How these two inhibitory receptors synergize to hinder antitumor immunity has been partially described by Andrews et al. [214], who have shown how CD8+ T cells lacking both PD-1 and LAG-3 show enhanced tumor clearance and improved survival in mouse models of melanoma, outperforming cells deficient in either receptor alone. Here, PDCD1 is linked to melanoma.